Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 8/20 | 0.70 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8128829 | 0.90 | ADK (0.69) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL8217778 | 0.87 | ADK (0.90) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL8155291 | 0.86 | ADK (0.77) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL8185081 | 0.86 | ADK (0.77) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL2034137 | 0.83 | ADK (0.72) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL2034226 | 0.83 | ADK (0.65) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL2036029 | 0.83 | ADK (0.83) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL8144545 | 0.82 | ADK (1.00) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL2032792 | 0.82 | ADK (0.73) | ADKPPARGNR2E3NCOR2KMT2A | |
| SCHEMBL2035633 | 0.81 | ADK (0.81) | ADKPPARGNR2E3NCOR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | claimed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | ADK 1/4885PPARG 2375/4885NR2E3 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.